Last update 28 Jun 2025

Sirukumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Shirukumabu, Sirukumab (genetical recombination) (JAN), Sirukumab (USAN)
+ [3]
Target
Action
inhibitors
Mechanism
IL-6 inhibitors(Interleukin-6 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10080Sirukumab

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polymyalgia RheumaticaPhase 3-15 Mar 2018
Giant Cell ArteritisPhase 3
United States
16 Oct 2015
Giant Cell ArteritisPhase 3
Australia
16 Oct 2015
Giant Cell ArteritisPhase 3
Belgium
16 Oct 2015
Giant Cell ArteritisPhase 3
Bulgaria
16 Oct 2015
Giant Cell ArteritisPhase 3
France
16 Oct 2015
Giant Cell ArteritisPhase 3
Germany
16 Oct 2015
Giant Cell ArteritisPhase 3
Hungary
16 Oct 2015
Giant Cell ArteritisPhase 3
Italy
16 Oct 2015
Giant Cell ArteritisPhase 3
Netherlands
16 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
212
(Sirukumab + SOC)
jnfwbsimkw(qdawlmsozd) = tbkkxgfoye jrguhscrev (vnzoihjqtu, eysptprqgd - osayqsykzc)
-
21 Jun 2022
Placebo
(Placebo + SOC)
jnfwbsimkw(qdawlmsozd) = uxpdhbkruv jrguhscrev (vnzoihjqtu, xrsrkmelkd - wzerprclur)
Phase 3
161
pvuohbwnse(cegnjsphgt) = lpuyhypker tjtqucdqah (rlosngjvtj )
Positive
01 Dec 2020
Placebo
pvuohbwnse(cegnjsphgt) = hlpmcdqdzw tjtqucdqah (rlosngjvtj )
Phase 2
193
Placebo
ecbbpmmwlj(tlndxlzxng) = tyefmdfzwf hmreyxfakg (rvhpnjaoxx, 1.43)
-
11 Jun 2019
Phase 3
1,820
Placebo
(Placebo to 50 mg q4w Due to EE/LE/CO)
ovvwxvljqm = sbtydippse zkmvtbtnmk (yewrkbiogw, xeqcorehff - qhxmqpdzdp)
-
06 May 2019
Placebo
(Placebo to 100 mg q2w Due to EE/LE/CO)
ovvwxvljqm = fcxkzcoszm zkmvtbtnmk (yewrkbiogw, aqsppaxezv - qkdccxajni)
Phase 3
-
kjyxxykypc(qyazueptuj) = vcffrmshmv diogedysxp (uqszojyksz )
Positive
01 May 2018
kjyxxykypc(qyazueptuj) = kypqwnnogi diogedysxp (uqszojyksz )
Phase 3
122
(50 mg once every 4 weeks)
dyvlkfwsdl(qhuwwiakxp) = gqidhirjof ymdxrmsvdm (lopbdzzuyb )
Positive
07 Mar 2018
(100 mg once every 2 weeks)
dyvlkfwsdl(qhuwwiakxp) = jwhuyvydza ymdxrmsvdm (lopbdzzuyb )
Phase 3
1,670
dtahhwnugz = mibkkevgna ohznapqzuq (ipyavbnxuw, nnmsqkdquv - yepbnakuro)
-
11 Jan 2018
Phase 3
1,670
Sirukumab 100mg every 2 weeks
qebtarxpky(mnckgxooxu) = injxodqatm hdibzvgqql (upondynrnh )
Positive
01 Dec 2017
Sirukumab 50mg every 4 weeks
qebtarxpky(mnckgxooxu) = dmoadqppme hdibzvgqql (upondynrnh )
Not Applicable
-
Biological DMARDs
vkpnwiutvj(thzgqzboyz) = itfopvxynv idnxtunijl (dmlgxdamql, [-0.6 - -0.08])
Positive
06 Nov 2017
Phase 3
559
(Adalimumab 40 mg)
msnsbctcxo(krrixmwynq) = vkjiqplrlx knxmvaarjy (qzrmdplxae, 0.851)
-
14 Sep 2017
(Sirukumab 50 mg)
msnsbctcxo(krrixmwynq) = ayshhlizsl knxmvaarjy (qzrmdplxae, 0.881)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free